| 51 |
20942779 | Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. | 2010 Oct |
1 |
| 52 |
21073556 | Antiplatelet drug interactions. | 2010 Dec |
1 |
| 53 |
21084035 | Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. | 2010 Dec |
2 |
| 54 |
19067731 | The genetics of antiplatelet drug resistance. | 2009 Jan |
1 |
| 55 |
19246723 | Clopidogrel resistance: pharmacokinetic or pharmacogenetic? | 2009 May |
1 |
| 56 |
19253920 | Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. | 2009 May |
3 |
| 57 |
19337788 | Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. | 2009 Mar |
2 |
| 58 |
19531897 | Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. | 2009 Aug |
2 |
| 59 |
18385991 | Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. | 2008 Jun |
2 |
| 60 |
18440347 | High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. | 2008 May |
1 |
| 61 |
18474675 | Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. | 2008 Aug |
1 |
| 62 |
19007592 | Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. | 2008 Nov 4 |
2 |
| 63 |
19544679 | Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4. | 2008 |
1 |
| 64 |
17261397 | Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. | 2007 Feb 1 |
3 |
| 65 |
17361128 | Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. | 2007 May |
2 |
| 66 |
17659194 | Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. | 2007 Jul 24 |
1 |
| 67 |
17697139 | Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. | 2007 Oct |
1 |
| 68 |
18004210 | Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. | 2007 Dec |
1 |
| 69 |
16503718 | Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma? | 2006 Mar |
1 |
| 70 |
16611111 | Thienopyridines and statins: assessing a potential drug-drug interaction. | 2006 |
3 |
| 71 |
16645157 | Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. | 2006 Aug |
5 |
| 72 |
16754899 | Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. | 2006 Jun 6 |
3 |
| 73 |
16875906 | A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. | 2006 Aug |
2 |
| 74 |
17008981 | Possible mechanisms of drug-induced aspirin and clopidogrel resistance. | 2006 Oct |
2 |
| 75 |
15604326 | Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. | 2005 Jan |
4 |
| 76 |
15679472 | Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. | 2005 Feb |
2 |
| 77 |
16113837 | The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. | 2005 Aug |
1 |
| 78 |
16264203 | Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction. | 2005 Nov |
1 |
| 79 |
14707025 | Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. | 2004 Jan 20 |
7 |
| 80 |
12485953 | The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. | 2003 Jan |
9 |
| 81 |
12515739 | Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. | 2003 Jan 7 |
2 |
| 82 |
12925453 | Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. | 2003 Aug 26 |
4 |
| 83 |
14522569 | Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. | 2003 Oct |
1 |